Blog: ALLARITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 7.01 Regulation FD Disclosure

On August 2, 2022, Allarity Therapeutics, Inc. (the “Company”) issued a press
release announcing that its Board of Directors has mandated a refocus of the
Company’s oncology pipeline strategy away from development of monotherapies
towards development of more promising and clinically relevant combination
therapies. The full text of the press release is furnished as Exhibit 99.1 to
this Current Report on Form 8-K. and is incorporated herein by reference.

The information reported under Item 7.01 in this Current Report on Form 8-K,
including Exhibit 99.1, is being “furnished” and shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, regardless of any general
incorporation language in such filing. This Current Report on Form 8-K will not
be deemed an admission as to the materiality of any information contained

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit   Exhibit Description
99.1        Press Release announcing "Allarity Therapeutics Refocuses Oncology
          Pipeline Strategy Towards Combination Therapies" dated August 2, 2022
104       Cover Page Interactive Data File (embedded within the Inline XBRL


© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s